Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary NeuroMetrix Reports Q1 2017 Financial Results
Revenue of $4.3M is up 89% year-over-year Quell device shipments of 18.7K and electrode reorders of 25.4K represent new quarterly highs Quell retail availability expands to nearly 3,000 stores WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO), today reported financial and business
View HTML
Toggle Summary NeuroMetrix Announces Availability of Quell Wearable Pain Relief Technology at Bed Bath & Beyond
Waltham -based company expands availability into brick-and-mortar locations of leading domestic and home merchandise retailer WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) today announced the availability of its flagship product, Quell ® , at select number of Bed Bath & Beyond
View HTML
Toggle Summary NeuroMetrix Named a 50+ Innovation Leader
Inaugural initiative of AARP and MedCity News showcases companies and people delivering cutting-edge healthcare solutions for the 50+ market MOUNTAIN VIEW, Calif. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it was selected as one of the healthcare industry's 50+
View HTML
Toggle Summary NeuroMetrix, Inc. Announces Date for 2017 First Quarter Financial Results Conference Call
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix , Inc. (Nasdaq: NURO) announced today that it plans to issue its 2017 first quarter financial results before the opening of the market on Thursday, April 20, 2017. The Company will host a conference call at 8:00 a.m., Eastern Time on April 20, 2017 to
View HTML
Toggle Summary NeuroMetrix Brings Quell Wearable for Pain Relief to American Academy of Pain Medicine 33rd Annual Meeting
Waltham -based company to exhibit its wearable device for widespread pain relief ORLANDO, Fla. --(BUSINESS WIRE)-- Coming together with thousands of leading clinicians who treat patients with chronic pain, NeuroMetrix, Inc. (Nasdaq: NURO) will exhibit Quell ® , its FDA -cleared, 100% drug-free
View HTML
Toggle Summary NeuroMetrix Gaining Increased Media Coverage of Quell Wearable Pain Relief Technology in 2017
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) reported increased media attention in 2017 on the company's Quell ® Wearable Pain Relief Technology™. An Inside Look at the Latest Health Tech - The Dr. Oz Show 3 Amazing New Gadgets to Relieve Aches & Pains - Fox News Could this
View HTML
Toggle Summary NeuroMetrix Announces Availability of Quell Wearable Pain Relief Technology at Best Buy
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that Quell ® will be available in over 450 Best Buy ® stores nationwide beginning in mid-February and is now available for purchase on BestBuy.com . "More and more consumers are proactively looking for technology to
View HTML
Toggle Summary NeuroMetrix Reports Q4 and Full Year 2016 Financial Results
2016 revenue $12.0M up 65% year-on-year; Q4 revenue $3.7M up 36% Quell device shipments of 14.3K and electrode reorders of 20K represent new quarterly highs WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO, NUROW), today reported financial and business highlights for the quarter
View HTML
Toggle Summary NeuroMetrix, Inc. Announces Date for 2016 Full Year and Fourth Quarter Financial Results Conference Call
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ: NURO, NUROW) announced today that it plans to issue its 2016 full year and fourth quarter financial results before the opening of the market on January 26, 2017 . The Company will host a conference call at 8:00 a.m., Eastern Time on
View HTML
Toggle Summary NeuroMetrix Reports Strong Quell Demand in Q4 2016
Invoiced Value of Quell Shipments Up 19% Over Q3 2016 WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (the "Company") (Nasdaq: NURO, NUROW) reported Q4 2016 demand highlights for its Quell ®  Wearable Pain Relief Technology™. During Q4 2016 the invoiced value of Quell shipments totaled
View HTML